Measuring interictal burden among people affected by migraine: a descriptive survey study

Table 3 Multivariable linear regression model of MIBS-4 scores (interictal burden). A positive estimate suggests the characteristic is associated with worse interictal burden; a negative estimate suggests it is associated with lower interictal burden

Characteristic	Estimate	SE	95% CI^a	p-value^a
HIT-6 score	0.14	0.02	0.10, 0.19	< 0.001
Monthly migraine day	0.09	0.03	0.04, 0.15	< 0.001
Monthly headache day	0.07	0.02	0.02, 0.12	0.003
Depression
No	0.00	–	–	–
Yes	0.74	0.34	0.08, 1.40	0.03
Anxiety
No	0.00	–	–	–
Yes	0.00	0.34	−0.67, 0.66	> 0.9
Employment status
Part−/Full-time	0.00	–	–	–
Other^b	− 0.41	0.35	−1.09, 0.27	0.24
Retired	−0.72	0.44	−1.59, 0.15	0.11
Satisfied with treatment regimen^c
No	0.00	–	–	–
Yes	−0.30	0.26	−0.81, 0.20	0.24
CGRP mAb treatment (3+ months)
In the last 3 months	0.00	–	–	–
In the past	0.69	0.41	−0.11, 1.50	0.09
Never	−1.42	0.37	−2.14, −0.69	< 0.001
Sex
Male	0.00	–	–	–
Female	−0.37	0.27	−0.91, 0.17	0.18
Age (years)	−0.02	0.01	−0.04, 0.01	0.15
Country
US	0.00	–	–	–
Germany	0.48	0.28	−0.07, 1.03	0.09

R² = 0.358; Adjusted R² = 0.341; Statistic = 21.1; p-value = < 0.001; AIC = 2490; BIC = 2554; N = 506
CGRP Calcitonin-gene related peptide, CI Confidence Interval, HIT-6 Headache Impact Test, mAb monoclonal antibody, SE Standard Error
^a95% CIs and p-values are exploratory
^bUnemployed, unable to work due to health issues, student, homemaker, other
^cYes: Satisfied or very satisfied with all treatments taken (acute/preventive/CGRP mAb treatment)

ISSN: 1129-2377